Sökning: onr:"swepub:oai:lup.lub.lu.se:e2639370-d4b4-422a-98e4-7d7b4804d73a" > Estimating the harm...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05584naa a2200637 4500 | |
001 | oai:lup.lub.lu.se:e2639370-d4b4-422a-98e4-7d7b4804d73a | |
003 | SwePub | |
008 | 161111s2016 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/243955 | |
024 | 7 | a https://lup.lub.lu.se/record/e2639370-d4b4-422a-98e4-7d7b4804d73a2 URI |
024 | 7 | a https://doi.org/10.1002/cncr.301922 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/2439552 URI |
040 | a (SwePub)lud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Carlsson, Sigrid V.u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xcasig |
245 | 1 0 | a Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice : A microsimulation screening analysis |
264 | c 2016-07-26 | |
264 | 1 | b Wiley,c 2016 |
300 | a 8 s. | |
338 | a electronic2 rdacarrier | |
520 | a BACKGROUND: Prostate-specific antigen (PSA) screening and concomitant treatment can be implemented in several ways. The authors investigated how the net benefit of PSA screening varies between common practice versus “good practice.”. METHODS: Microsimulation screening analysis (MISCAN) was used to evaluate the effect on quality-adjusted life-years (QALYs) if 4 recommendations were followed: limited screening in older men, selective biopsy in men with elevated PSA, active surveillance for low-risk tumors, and treatment preferentially delivered at high-volume centers. Outcomes were compared with a base model in which annual screening started at ages 55 to 69 years and were simulated using data from the European Randomized Study of Screening for Prostate Cancer. RESULTS: In terms of QALYs gained compared with no screening, for 1000 screened men who were followed over their lifetime, recommended good practice led to 73 life-years (LYs) and 74 QALYs gained compared with 73 LYs and 56 QALYs for the base model. In contrast, common practice led to 78 LYs gained but only 19 QALYs gained, for a greater than 75% relative reduction in QALYs gained from unadjusted LYs gained. The poor outcomes for common practice were influenced predominantly by the use of aggressive treatment for men with low-risk disease, and PSA testing in older men also strongly reduced potential QALY gains. CONCLUSIONS: Commonly used PSA screening and treatment practices are associated with little net benefit. Following a few straightforward clinical recommendations, particularly greater use of active surveillance for low-risk disease and reducing screening in older men, would lead to an almost 4-fold increase in the net benefit of prostate cancer screening. Cancer 2016;122:3386–3393. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a early detection of cancer/adverse effects | |
653 | a mass screening | |
653 | a prostate-specific antigen/blood | |
653 | a prostatic neoplasms | |
653 | a quality of life | |
653 | a quality-adjusted-life-years | |
700 | 1 | a de Carvalho, Tiago M.u Erasmus University Medical Center4 aut |
700 | 1 | a Roobol, Monique J.u Erasmus University Medical Center4 aut |
700 | 1 | a Hugosson, Jonas,d 1955u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xhugjo |
700 | 1 | a Auvinen, Anssiu University of Tampere4 aut |
700 | 1 | a Kwiatkowski, Macieju Städtische Klinikum Braunschweig4 aut |
700 | 1 | a Villers, Arnauldu University of Lille4 aut |
700 | 1 | a Zappa, Marcou Cancer Research and Prevention Institute (ISPO)4 aut |
700 | 1 | a Nelen, Verau Provinciaal Instituut voor Hygiëne4 aut |
700 | 1 | a Páez, Alvarou Fuenlabrada University Hospital4 aut |
700 | 1 | a Eastham, James A.u Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Lilja, Hansu Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University of Oxford,Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli |
700 | 1 | a de Koning, Harry J.u Erasmus University Medical Center4 aut |
700 | 1 | a Vickers, Andrew J.u Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Heijnsdijk, Eveline A Mu Erasmus University Medical Center4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för urologi4 org |
773 | 0 | t Cancerd : Wileyg 122:21, s. 3386-3393q 122:21<3386-3393x 0008-543Xx 1097-0142 |
856 | 4 | u https://portal.research.lu.se/files/27487841/16811007.pdfx primaryx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1002/cncr.30192y FULLTEXT |
856 | 4 | u https://europepmc.org/articles/pmc5073010?pdf=render |
856 | 4 8 | u https://lup.lub.lu.se/record/e2639370-d4b4-422a-98e4-7d7b4804d73a |
856 | 4 8 | u https://doi.org/10.1002/cncr.30192 |
856 | 4 8 | u https://gup.ub.gu.se/publication/243955 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy